MedTrace Logo

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma

NCT06732232 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-12-13

No results posted yet for this study

Summary

This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologouschimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed/refractory multiple myeloma.

Conditions

Interventions

DRUG

CD19/CD20/BCMA CAR-T

CD19/CD20/BCMA CAR T therapy

Sponsors & Collaborators

  • Shanghai Cell Therapy Group Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Jinxing Lou · China, Shanghai Mengchao Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-12
Primary Completion
2027-12-12
Completion
2027-12-12

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06732232 on ClinicalTrials.gov